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3This guidance is indented as a practical tool for research professionals planning and conducting population 
studies. Main focus is on monitoring of iodine deficiency disorders (IDD), but much of it applies to any human
study. The guidance may be useful in many ways, for instance, for researchers planning studies, or personnel 
collecting biosamples or conducting laboratory analysis. It helps when writing the study plan and the study 
manual and furthermore, it may be used for educational and training purposes.
The guidance was written within the EUthyroid project, which aims to harmonize iodine and thyroid related 
studies in Europe. This is an important goal, because it improves the overall quality of studies as well as 
comparability of results. This guidance is one step towards harmonisation. 
The guidance is divided into three parts. Part A includes general recommendations and issues to consider 
when planning a study, including quality issues. Part B offers more detailed instructions and 
recommendations for specimen collection and sample handling. Part C gives an overview of iodine and 
thyroid related laboratory analysis.  References have been included to suggest useful reading, although the 
purpose of this document is not to serve as a comprehensive literature review.
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8PART A. PLANNING STUDIES
9Planning is a crucial succes factor in any research project. Planning for even the smallest monitoring studies
starts months before participants may be contacted. Large multinational studies take even more time to 
plan.
Monitoring studies and other observational research studies perfomed by universities and research
institutes are not as strictly regulated as studies performed by the pharmaceutical industry, which adheres to 
Good Clinical Practice (GCP) and Good Laboratory Practice (GLP). 
Research projects performed outside pharma require thorough planning also, but there is less published
material to guide researchers. Projects may be more variable by nature and the staff may be less
experienced. The strict timelines and requirements related to the ethical approval process has pushed
researchers to improve planning and quality of all types of human studies. But still, there is room for 
improvement.
1  The importance of good planning in research projects
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Planning of a succesful human study starts with a project plan, which is separate from a scientific research
plan. A good project plan helps in optimizing resources. Later, a project manual is needed,  serving as an 
everyday tool when conducting the study. The project manual should be finished well before the field work
actually begins. 
Detailed planning is important, because multiple factors affecting the ability of staff or participants to follow
instructions or collect samples adequately add unaccounted variability into laboratory results and other
measurements. 
When planning multicenter studies, cultural differences must be considered, because they impact on the 
communication between investigators, staff and participants. Also, they impact on how much and what kind
of information staff and participants can understand. The ability to learn from training, work under tight
time-schedules or adopt new technologies or methods vary greatly. In multilingual studies, translations may
be needed, so keep in mind that obtaining them and testing them in the right cultural context takes time.
Knowledge about and adherence to relevant regulations, laws and practices relating to clinical studies or
material logistics is crucial and vary from country to country. 
2 Planning and execution phases do not overlap
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A good project plan allows optimisation of resources and timelines, and reduces preanalytical errors. It is less
detailed than the project manual. Issues covered:
 Financing and budgets
 Legislatory requirements (ethical approvals etc.)
 Site selection
 Study design
 Recruitment plan (including events for participants)
 Pilot study
 Human resources (staffing and training plan)
 Material needs and logistics
 List of questionnaires
 Time-frame
 Risk management (mitigation and contingency planning = plan B)
 Documentation
3 The project plan optimises resources
12
 Background and aims, recruitment criteria, study design, treatments, financing, approvals 
 Organizational structure, staffing needs (including substitutes), task descriptions 
 Staff training, staff motivation events, staff safety
 Timetables
 Lists of materials (equipment, questionnaires, laboratory materials, sampling materials)
 Logistics 
⁻ Specifications of equipment, sampling materials, questionnaires etc.
⁻ Sample collection charts (sampling volumes, order of blood collection tubes etc)
⁻ Sample labelling and identification system
⁻ Biobanking (sample storage instructions) 
 Field work
⁻ Work flow, process charts
⁻ Instructions for patient preparation and visits, patient materials 
⁻ Detailed description of  tasks, measurements, methods, procedures (incl. waste handling plan)
 Data management instructions, documentation instructions
 Safety of participants, staff and data
 Quality assurance procedures
 Instructions  regarding  contacts with participants 
 Information about dissemination 
 Examples of project manuals , see Tolonen et al. 2016 or Lundqvist and Mäki-Opas 2016 
4  The project manual – an execution tool with a practical content
Tolonen et al. 2016,  Lundqvist and Mäki-Opas 2016. 
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The goals of research laboratories and clinical laboratories overlap partly, but there are significant
differences too.  Quality issues are important for both, but for different reasons
Clinical laboratories analyzing patient samples are typically accredited and their operations are largely based
on automation and a commercial laboratory system. Speed, patient safety and diagnostic accuracy are
emphasized. Large numbers of samples can be analyzed with high quality, which is a major strength. 
However, tailoring of laboratory processes for the needs of research projects is often not possible.
Research laboratories typically work in a state of constant change, tailoring methods and processes, and 
focusing on scientific progress and development. A high quality level cannot be emphasized enough, because
it prevents waste of resources and inaccurate interpretations.
Performing the actual analysis is an important step in obtaining high-quality laboratory results. However, 
studies have shown that the pre-analytical and post-analytical phases are even more important, because 
most of the errors occur there.
5 Laboratory quality
Plebani et al.2017
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Pre-analytics has a major impact on the quality of any human study collecting biological samples. The term 
covers a wide range of factors affecting the early phase of the laboratory process, such as patient 
characteristics, choice of sample type and mix-ups during sample collection.
Pre-analytical sources of variability can be divided to four categories,  relating to:
 test or biomarker
 patient preparation
 specimen collection
 specimen processing, transport and  storage
6 Pre-analytical factors – what are they?
Simundic et al. 2012
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In the final post-analytic phase laboratory results are transferred to clinicians or researchers who interpret 
them and turn them into information, decisions and recommendations. Handling of the data is an important 
step, because errors are easily created when data is being transferred. Up-to-date and well-functioning data 
communication systems prevent losing or unintentionally changing data.  
Another type of vulnerability is the interpretation of laboratory results. Inappropriate interpretations is a 
highly relevant problem in academic research environments, because of the high turn-over of staff and use of 
student work-force.  
Staff competency is a crucial success factor in all phases of laboratory medicine and research. Limited 
knowledge in laboratory medicine or inexperience in interpreting laboratory data may easily yield incorrect 
interpretations. When hypotheses are rejected based on inaccurate assumptions or results over-
exaggerated, it is a serious problem. Resources may be wasted and scientific efforts taken in the wrong 
direction.
A functioning dialogue between the laboratory and researchers using the data is crucial to prevent misuse of 
data and optimal use of resources. Ideally it is set up at the early stages of project planning and kept up until 
results or recommendations have been published.  
7 Post-analytical phase – turning data into information
Plebani et al. 2017
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Ideally, monitoring is part of national health-examination surveys (HES). Choosing a representative sample of 
the population, with sufficient sample size, minimises the risk of incorrect interpretation of results due to 
chance error or selection bias. Unfortunately, samples from vulnerable groups are not always collected in 
HES. Therefore, less representative samples from smaller research projects are often accepted for monitoring
purposes. In these cases too, the information may be useful, although more suggestive by nature.
The European Health Examination Survey (EHES) Manual provides guidelines and specifies the requirements 
for implementation of standardized national health examination surveys (HES) in the European countries.
http://www.ehes.info/manuals/EHES_manual/EHES_manual.htm
The WHO STEPS Surveillance Manual: The WHO STEPwise Approach to Chronic Disease Risk Factor 
Surveillance provides similar guidelines, especially suitable for developing countries. 
http://www.who.int/chp/steps/STEPS_Manual.pdf?ua=1
8  Obtaining samples for monitoring purposes
17
A laboratory with a high quality level should be chosen. Accredited laboratories are recommended, because
they comply with international standards for requirements of testing laboratories (e.g. ISO/IEC 17025:2005) 
and furthermore, they are regularly audited. Research laboratories are typically not accredited, but they also
need to show that analyses are performed with sufficient quality. An existing quality system is one proof of 
quality.
The quality system of the laboratory should cover at least the following topics:
 Management part: management system, documentation/record keeping system, internal/external
audits, corrective preventive actions
 Technical part: lab environment, staff competency, equipment, laboratory methods, method
validation, quality assurance, proficiency testing, reporting system, known measurement
uncertainty
9 Choosing laboratory
CLSI. 2011.
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 Median urinary iodine concentration (UIC) is a well-validated biomarker of iodine intake
 Established recommendations and cut-off values for different levels of deficiency exist. They are issued 
by WHO and are based on spot urine UIC
 UIC is considered a sensitive indicator of recent iodine intake. 
 Inclusion of at least 100 subjects is generally recommended for spot samples to estimate population 
median. The exact number depends on the distribution of UIC and may vary. 
 Between-day variability of UIC is high and therefore about 10 spot samples are required to reliably 
estimate intake on an individual level. 
 Urinary iodine can also be measured in relation to creatinine excretion to correct for differences in urine 
volume and sample dilution. It is useful in some population groups, however, this approach brings other 
types of variability into the results, and may be problematic in regions with malnutrition. 
 24-h urine samples are sometimes used to reduce variability, but lack of comparable data as well as 
reduced compliance or participation may outweigh the benefits.
10  Choosing biomarker for iodine intake – urinary iodine
concentration (UIC)
Knudsen et al. 2000, Rasmussen et al. 2002, WHO 2007, 
Zimmermann 2009, Karmisholt et al. 2014, Perrine et al. 2014, 
Pearce and  Caldwell  2016. 
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 Tg is a thyroid-specific glycoprotein 
 Precursor and storage site for thyroid hormones T3 and T4
 Reflects iodine nutrition over a period of weeks/months
 Elevated in goitre, iodine deficiency/excess, thyroid disorders
 Normal range in adults: 3-40 µg/L
 Serum-Tg is a more sensitive marker of iodine status in children and adults than other thyroid tests (e.g. 
TSH, FT4)
 Thyroglobulin antibodies (TgAb) are common in adults and cross-react with Tg
 If Tg is measured for adults, TgAb should also be measured. This is less important for children’s studies
 Dried blood spots (DBS) are also used because they are easy to collect and transport
 Results are method dependent and not easily standardized, making it difficult to compare results 
obtained by different methods
11  Choosing biomarker for iodine intake – thyroglobulin (Tg) 
Rasmussen et al. 2002, Vejbjerg et al. 2009, Krejberjer et al. 2015
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Thyroid hormone measurements are useful for identifying abnormal thyroid function. Useful thyroid 
function biomarkers are thyroid-stimulating hormone (TSH), free thyroxine (FT4) and thyroglobulin (Tg). 
Total T4 can be of additional value in specific cases, such as pregnancy or disorders in binding proteins. 
Thyroid peroxidase autoantibodies (TPOAb), thyroglobulin autoantibodies (TgAb) and TSH receptor 
autoantibodies (TRAb) may help to clarify the cause of thyroid dysfunction.
Thyroid hormone and antibody levels are altered by changes in iodine intake. However, the thyroid’s ability
to adapt to changes in iodine intake varies between individuals. Also, several factors affect thyroid hormone
levels (e.g. thyroid related autoimmune diseases, genes, pregnancy). Therefore, thyroid hormone levels
alone cannot be used to estimate iodine intake in populations, other measures of iodine intake are also
needed.
12  Choosing the right thyroid biomarkers
Bjergved et al. 2012, Ittermann et al. 2015, Pearce and Caldwell 
2016, Bliddal et al. 2017, McLachlan and Rapoport 2013
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Standardisation of iodine measurements is possible, because adequate reference materials and an external 
quality assessment scheme are available.
Ensuring the Quality of Urinary Iodine Procedures Program (EQUIP):
 Organized by the Centers for Disease Control and Prevention (CDC).
 3 rounds per year, free of charge
 Participation highly recommended
 Results are traceable to NIST standard reference materials with certified mass concentration values 
(SRM 2670a) and reference mass concentration values (SRM 3668).
 Laboratories may purchase the same reference materials from NIST that EQUIP uses to recalibrate their
method (if EQUIP results indicate a need for that). However, it should be kept in mind that such a 
procedure does not improve repeatability or correct for poor method performance.
In the EUthyroid project, iodine measurements from the national and regional IDD monitoring studies will be 
standardised by a centralized laboratory at the National Institute for Health and Welfare (THL) in Helsinki, 
Finland.
13  Standardisation of urinary iodine measurements
Makhmudov and Caldwell 2011
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For TSH,  standardisation to a reference measurement procedure is not possible, because a reference
material with certified mass-concentration value is not available. Most methods are traceable to WHO 
International standard (80/558), which is obtained from cadaver pituitary and is non-commutable. However, 
harmonisation of laboratory methods and procedures is a realistic aim, making the results more agreeable
and comparable (although not necessarily more accurate).
External quality assessment schemes (EQAS) are highly recommended. Several programs are available 
including Labquality, NEQAS, etc. Participation in EQAS shows how results from one laboratory or method
relate to others. However, it does not make the results more accurate, partly because EQAS methods suffer
from similar standardisation problems as the individual methods. 
The need for harmonisation has been widely recognised. The Committee for Standardization of Thyroid
Function Test (C-STFT) and equipment manufacturers recently joined their efforts and work towards
improved harmonisation of thyroid related measurements.
In the EUthyroid project thyroid biomarkers measured in national and regional IDD monitoring studies are 
standardised by a centralised laboratory at the National Institute for Health and Welfare (THL) in Helsinki, 
Finland. This allows standardisation of results and a comparison of thyroid hormone status in Europe.
14  Harmonisation of thyroid related measurements
Greenberg 2014, Faix and Miller 2016. 
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 Lacking or superficial study manual
 No pilot study performed (difficult steps should be rehersed)
 Poor staff training (insufficient training generally or lack of trained substitutes)
 Data linkage not possible (e.g. errors in the labelling system linking participant with forms and samples)
 Human errors (e.g. mix-ups when collecting, labelling or aliquoting specimens)
 Wrong choice of specimen, specimen not suitable for specific biochemical analysis
 Inadequate participant preparation
 Poor adherence due to unclear instructions (diet, fasting time, medications, smoking, physical activity
sampling time)
 Lack of sample rejection criteria
 Unorganised documentation (e.g. lack of sampling documentation or lack of documentation of 
unexpected events during sample lifespan)
 Inadequate sample storage or shipment temperature
 Lack of laboratory audits
 Poor quality of laboratory measurement
 Post-analytic phase: insufficient measurement of confounders or inadequate adjusting for them
15  Typical pitfalls
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Types of costs (examples):
Direct costs
 Intervention, side effects/adverse events, medications, personnel, transportation, materials, 
equipment, subcontracting
Indirect costs
 Productivity loss, time costs
(Intangible costs)
 Non-monetary costs
16  Analyzing costs  
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Steps of a cost-analysis:
Identification of resources/services
 What resources are needed for monitoring activities?
 What services are provided to the population?
Investigation of quantities
 How often on average are resources/services needed/provided?
 Database for quantities of resources/services
Collection of prices
 Price per resource?
 Database for prices 
Determination of costs
 What?  How often? Price? Proportion of the population?
 Database for costs
16  Analyzing costs - continues 
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PART B.  
SPECIMEN COLLECTION AND 
SAMPLE HANDLING
27
 Different standards and practices related to sample collection are applied in different countries and vary
between institutions within a country
 For phlebotomy, WHO’s guidelines may be used to establish standard operating procedures.
 A new standard for blood sample collection was recently published by CLSI
 When planning a study and preparing SOP’s, it is important to follow local practices. The staff has
usually been trained locally and changing old habits is surprisingly difficult. 
 All laboratory specimens should be handled as infectious and standard precautions applied
 Detailed written instructions on sample collection and treatment should be at hand for staff performing
sample collection. This includes diagrams with order of blood draw, types and number of blood
collection tubes, number of aliquots, etc. Priority list for use of samples in the laboratory should also be
available to staff.
1  Sample collection - standards and practices
WHO 2010, CLSI 2017. 
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 Clear instructions on dietary restrictions must be given
− Fasting
− Intake of liquids (water as usual, no caffeine containing beverages or other drinks)
 Smoking should be refrained from
 Medications – thyroid medications are usually not taken on the morning of sampling
 Physical activity - avoid heavy physical activity prior to sampling
 Timepoint of blood sampling must be given
− Morning is preferred
− Circadian rythm plays a role - not always possible to collect sample at ideal time of day
 Timepoint of sampling should be given
2 Participant preparation in advance
29
 Identify the participant
 Obtain consent
 Record all relevant information about the participant: name, ID, date and time of sampling, fasting time, 
hours urine has been in bladder, medications
 Explain the sampling procedure to the participant in detail
 Ask if the participant is anemic or whether any condition or impediment hindering sample collection 
exists
3 Participant reception at study site
Woodcock et al. 2010 
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 Unique identification must be used to link participants to their consent, questionnaires and laboratory
samples.
 All forms and sample collection tubes/vials must contain a label with the participants unique
identification number. 
 Labelling sheets with participants’ all labels should be prepared beforehand. 
 On the first visit to the study site, the participant receives a random number/labelling sheet, which is 
used throughout the study.
 Crucial step – any vials or forms lacking unique identifier should be discarded, any potential mixups
must be immediately and reliably recorded.
 If labels are printed out when particant arrives to the site, problems with data systems may slow down
sample collection and be very annoing for the participant
 Suitability of label materials for storage in deep-freezing temperatures should be tested beforehand.
4  Identification by using a unique indentifier
31
A label with a unique identifier should be attached to all samples and forms obtained from a participant
32
5.1  Workplace preparation
Materials needed:
 Toilet with shower head or towelettes
 24h sample:
− Urine collection cup or a specimen collection pan 
that fits in the toilet
− Urine storage container (brown or orange 
container with volume scale is preferred)
 Spot sample:
− Urine collection cup with integrated transfer 
device or urine collection cup/bag with transfer 
straw 
 No stabilizers in urine tubes allowed unless suitability 
tested for iodine measurements. 
 If dipstick testing is performed, part of the sample 
should be poured into a separate tube for that purpose
 Labels
Supplies should only be used until the declared expiry date.
5 Urine sampling
Urine collection cup with an integrated 
transfer device
ECLM 2000, CLSI 2009
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 Aim for a clean catch specimen to avoid bacterial growth in sample
 Wash your hands with soap and warm water
 Female:
− with a towelette or hand shower, cleanse the urethral meatus and surrounding area from the 
front to the back
 Male: 
− withdraw the penis foreskin and with a towelett or shower, cleanse the glans and urethral
opening from the front to the back
 Infants:
− cleanse the entire pubic and perineal areas and dry them
5.2  Urine sample collection
5.2.1  Cleansing
ECLM 2000, CLSI 2009
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A 24h sample collection may start at any time during the day, but usually it begins in the morning. 
 Empty bladder into the toilet (this urine is not collected). Write down the starting time.
 During the following 24 hours, collect all urine passed into a collection cup.
 Pour the urine into a storage container each time you urinate. Keep the storage container cold and 
protected from light. The sample must not freeze.
 24 hours after the start time, urinate again at the same time, to finish the collection process. Write 
down the time.
 Document unexpected events (e.g. losing part of the sample, strong sweating because of sauna, 
physical stress etc).
 Document the use of medications during sample collection.
Once the urine collection has been completed, the storage container should be taken to the lab (ASAP).
 Total sample volume and the quality of sample must be documented. Ensure that the catch is 
homogeneous. 
5.2.2  24h-sample 
ECLM 2000, CLSI 2009
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Collect the mid-stream urine specimen in a urine collection cup or bag.
 Hold your urethral opening open
 Allow the first urinary flow to escape, collect the mid-stream urine and finish urinating into the 
toilet bowl
 Do not touch the inside of the collection cup
Infants
 Place an adhesive urine collection bag over the infants’ genital area and wait until it is filled.
OR
 Collect the sample in a urine collection cup by placing the cup into the front of a potty.
OR
 Collect the urine in a pad placed inside a diaper (only pads tested for this purpose may be used). 
5.2.3  Spot sample
ECLM 2000, CLSI 2009, Dorey and Zimmermann 2008
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5.2.4  Sample transfer to the collection tube
 Performed by patient or staff, depending on study
 Follow separate instructions from your laboratory. 
 Generally:
− Label cups and tubes as instructed
− After collection of the urine sample, close the urine 
collection cup tightly
− Transfer part of the sample into the urine tube that
will be taken to the laboratory. Mix the urine 
sample before transferring it (do not shake)
− Store the tube as instructed
− Dispose surplus sampling materials 
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6 Urine sample handling
Materials
 Pipette
 Storage tubes
 Storage boxes
 Disposable gloves
6.1  Workplace preparation
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6.2  Sample transfer to the storage tubes
 Label storage vials
 Pipette aliquots into storage vials, close caps
 Place the vials into the storage boxes, label boxes 
and place them into the freezer
 Temperature -20 oC or colder
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7 Blood sampling
Materials:
 Disinfection solution (>80 % alcohol )
 Blood collection tubes
 Needle with integrated needle holder
(new standard) 
OR
 Needle + needle holder
 Tourniquets
 Swabs, gauze pads, skin tape, 
bandages
 Disposable gloves
Supplies should only be used until the 
expiration date.
7.1  Workplace preparation
CLSI 2017
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 Ask participant to remove tight clothes that might constrict the upper arm
 Participant should be sitting in a comfortable chair with arms to provide support in case the patient 
faints
 If possible, the participant should remain in sitting position five to ten minutes prior to blood sampling
 Participant’s position: hand downward, palm upwards
 Use gloves or disinfect hands 
 Phlebotomy may be performed by qualified personnel only
7.2  Blood sample collection
7.2.1  Preparing for blood sampling
Alfthan et al. 2016
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7.2.2 Blood sampling
Blood sampling instructions with the vacuum technique:
 Apply tourniquet (not necessary if vein is easy to find)
 Select vein
− The median cubital vein is the first choice for blood collection. This
vein is usually large, visible, well anchored and does not bruise easily.
− The cephalic vein is the second choice for blood collection. It is not as 
well anchored and may be more difficult to find.
− The basilic vein is the third choise for blood collection. This vein tends
to roll away and bruise more easily.
 Clean the site with disinfectant, let dry
 Venipuncture and start filling the tubes in the specified order
 Loosen the torniquet immediately when the bloodstream runs
 Fill the tube
 When the tube is filled and the bloodstream stops, take the tube
out of the holder
 Check that the tube is filled to the adequate volume
 If several types of blood samples are collected, the order of draw
is citrate → serum → heparin → EDTA. Do not take the needle out 
from the vein when changing tube. 
Alfthan et al. 2016, CLSI 2017
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 Immediately after removing the holder, mix the serum tube by inverting it top-down 5-10 times
(depeding on the manufacturers’s instructions)
 Store the tubes in a vertical position until sample handling
 Apply the gauze and remove the needle from the vein
 Apply pressure on the punctured site with the gauze until bleeding stops and bandage the arm
 Dispose all surplus sampling materials according to your facility’s policy 
 Label the tubes in the presence of the participant
 Document the number of sample tubes, time of sampling and unexpected events during sample 
collection
 Examples of unexpeted events:
− Stasis not opened: Prolonged venous occlusion can cause changes in the concentration of blood
constituents.
− Participant lying down during sampling: The position of the subject can influence some of the 
measured values.
7.2.3  After blood sampling
Alfthan et al. 2016
43
8 Blood sample handling
Materials
 Centrifuge
 Pipette
 (Pooling tube)
 Storage tubes
 Storage boxes
 Disposable gloves
Separate serum or plasma according to manufacturers’ instructions
Serum should be separated within 60 minutes (at the most)
8.1  Workplace preparation
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8.2  Centrifugation
 Place the sample tubes in the centrifuge
 Check that all tubes are resting on the bottom of the 
centrifuge rack and that the centrifuge rotor and tubes are in 
balance
 Centrifuge the tubes according to manufacturer’s instructions
(typically at about 1000 g at room temperature)
 After the centrifugation check that serum has been separated
properly
Well-separated serum samples
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8.3  Hemolysis
 Hemolysis means the destruction of red blood cells and the release of hemoglobin into the surrounding 
fluid.
 If the classification of hemolysis is based on visual inspection, a photograph of different degrees of 
hemolysis should be kept close by
1  Not hemolysed
2  Slight hemolysis
3  Moderate hemolysis
4  Gross hemolysis
Alfthan et al. 2016
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8.4  Sample transfer to the storage tubes
 If you have more than one sample tube, separate the 
serum from the sample tubes into a pooling tube and mix 
gently
− If one of the samples is hemolysed, do not mix it with 
the others
 Document the quality of samples (hemolysed, lipemic, 
icteric), the abnormal sample amount and which storage
vials contain abnormal sample
 Label storage vials – use labels which have been tested for 
your process
 Pipette aliquots into storage vials, close caps
 Place the vials into the storage boxes, label boxes and place
them without delay into the freezer (-70 oC)
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9 Dried blood spot (DBS) sampling
 Position hand palm-side up, choose least calloused finger
 Clean fingertip with alcohol, let air dry
 Hold the finger, place sterile lancet off-center to the fingertip, firmly
press the lancet into the tissue
 Wipe away first drop of blood
 Invert the finger, allow a large drop of blood to form on the tip of the 
finger, touch it to circle on filter card
 Apply 1 drop per circle, the circle has to be completely filled, blood has
to soak through the paper
 Label the card, air-dry for 24h, store at -20°C in sealed plastic bag
(several cards per bag)
48
10  Common mistakes when taking DBS and tips to improve spot
size and quality
 Blood drop too small → circle on card not
completely filled or paper not soaked
through
 Several blood drops applied to 1 circle
 Finger was touched to the filter card, blood
smeared
 Squeezing/milking the finger too hard
therefore ”diluting” the blood
 Card did not dry sufficiently
 Warm up finger by massage, kneading it / 
rotating arm
 Press lancet down firmly, use at 
least2x1.5mm lancet
 Hold finger below height of heart while
waiting for drop to form
 if blood flow stopped, wipe the finger, 
maybe it was already clotted
 Softly (!) press the finger to increase blood
flow
 Find which finger works best (index finger is 
not recommended)
 Maybe ask for a second prick on another
finger
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Clear documentation instructions for all procedures must be prepared beforehand. Deviations from
instructions should be documented in an organized way. Comments from entire sample lifespan should be
collected. A coding system should be developed beforehand and piloted. After that it is ideally kept
unchanged throughout the project. Space for free-text comments should be given, but should be exceptions, 
because they are more difficult to use later.
Typical neglections:
 Inappropriate coding system or poor adherence to it by staff
 Events during specimen collection (e.g. patient position, prolonged tourniquet application) not
documented
 Time of specimen collection and fasting time not documented
 Quality of sample not documented
 Sample comments not available from entire sample lifespan
 Sample rejection criteria lacking
 Lacking visual inspection of sample
 Documentation of lipemia or degree of hemolysis lacking
 Number of freeze-thaw cycles not reliably documented
11  Documentation
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 Plan the sample shipments in advance
 Make sure that appropriate shipment conditions will be retained during the whole shipment (e.g. frozen
samples)
 Use reliable courier
 The shipment has to be packed according to IATA (International Air Transport Association) regulations
 Packing should be done according to relevant packing instruction
 Regulations should be followed when using dry ice
12  Sample shipment
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C. LABORATORY ANALYSIS
52
 Urinary iodine concentration (UIC) is used to define the iodine status of populations.
 The most commonly used methods are based on the Sandell-Kolthoff reaction. It is a relatively
economical option and the method can be set up in any laboratory. However, the staff needs to be
relatively skilled, because the method is not among the simplest ones.
 The gold standard method is inductively coupled plasma - mass spectrometry (ICP-MS) . This method
requires a suitable laboratory environment with more expensive equipment. The staff should be highly
skilled and experienced, with special know-how in performing mass-spectrometric analyses and 
maintaining a suitable laboratory environment.
 In the EUthyroid project, UIC from various European studied are compared after a standardisation based 
on reanalysis of a subset of samples from each study. The analyses are performed by ICP-MS at the 
National Institution for Health and Welfare (THL). 
1  Urinary iodine concentration (UIC) 
Shelor and Dasgupta 2011, Pearce et al. 2016 Völzke et al. 2016
53
1.1  ICP-MS method
Inductively coupled plasma - mass spectrometry 
(ICP-MS) ionizes the sample with inductively 
coupled plasma and then uses a mass 
spectrometer to separate and quantify specific 
ions. ICP-MS is capable of detecting metals and 
several non-metals at very low concentrations.
Urinary iodine is usually measured by preparing 
the samples in basic solution (using TMAH or 
NH4OH).
Ce4+(yellow) + As3+ Ce3+(colorless) + As4+
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1.2  Sandell-Kolthoff Reaction
In the Sandell–Kolthoff reaction, iodide catalyzes 
the reduction of yellow ceric ion to the colorless 
cerous form in the presence of arsenious acid. 
Impurities present in urine may hamper the 
analysis. Usually, the sample is pretreated by 
alkaline ashing or by acidic or basic digestion.
When using a method based on the Sandell-
Kolthoff reaction, it is important to use
calibrators and controls in the same
concentration range that your samples exhibit. 
Within the same country, some population
groups can show high UIC values while others, 
especially vegans, may have very low UIC values. 
I-
Elorinne et al. 2016
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Less common methods include:
 Gas chromatography mass spectrometry (GC-MS)
 Inductively coupled plasma atomic emission spectrometry (ICP-AES)
 Atomic absorption spectrometry (AAS)
 Capillary electrophoresis (CE)
 Flow injection analysis (FIA)
 Instrumental neutron activation analysis (INAA)
1.3  Other methods
Khazan et al. 2013
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 Fasting status – lower values obtained for samples collected after fasting - record status and hours of 
fasting
 Within-day variation – mainly caused by variation in intake during the day and possibly circadian rythm
 Lower UIC expected in the morning compared to the afternoon
 Iodine is stable during long-term storage in the freezer
 Shipping or storage in non-freezing temperature presents a problem to quality of urine sample, rather
than stability of iodine
 Repeated freeze-thaw cycles is not a problem
 Use of iodine containing drugs may affect iodine concentrations – rare problem
 Stabilizers in urine collection tube may interfere with analysis - avoid stabilizers and if used, record it
 Suitability of all materials and reagents used for urine collection as well as analysis of iodine should be
tested to avoid contamination with iodine. Suppliers declare if materials are trace element free and 
suitable for ICP-MS analysis
 Dipstick contamination - Urine samples collected at antenatal clinics are often tested for glycosuria and 
proteinuria by using dipsticks. This may contaminate the sample, therefore dipstick testing should be
performed from a separate vial
1.4  Effect of preanalytical factors on UIC
Pearce et al. 2009 and 2016, Perrine et al. 2014, 
Mirjanic-Azaric et al. 2015
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 Serum and dried blood spot Tg are used to define the iodine status of populations
 Suitable especially for children, because Tg autoantibodies are less prevalent compared to adults
 Radio-immunoassay (RIA) and various immunoassays with varying functional sensitivity can be used to 
determine Tg
 Recently, a new low-cost serum and DBS-Tg sandwich enzyme-linked immunosorbent assay was 
developed
2  Thyroglobulin (Tg) measurements
Pearce et al. 2016 
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2.1  Principle of sandwich ELISA method
Stinca et al.  2015
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 No effect of repeated freezing and thawing of sample
 No effect of 15-week storage in -20 oC
 Intra-individual variability ~14%
 Smoking increases Tg and must be accounted for
 Age should be accounted for
 TgAb are prevalent in adults and interfere with the Tg measurement
2.2  Effect of preanalytical factors on Tg
Knudsen et al. 2002, Stinca et al. 2015, Hillebrand et al. 2017 
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 Useful laboratory measurements include 
− TSH - Thyroid-Stimulating Hormone (Thyrotropin)
− FT4 - free Thyroxin
− FT3 - free Triiodothyronine 
− TPOAb - Thyroid Peroxidase Autoantibodies
− TgAb - Thyroglobulin Autoantibodies
− TRAb – THS Receptor Autoantibodies
− (TT4 - total Thyroxin,  rarely used nowadays)
 In EUthyroid, the most commonly used thyroid-related laboratory measurements are included
3 Thyroid function and autoantibody measurements
Pearce et al. 2016, 
McLachlan and Rapoport 2013 
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3.1  Clinical chemistry and immunoassay testing
Thyroid-related laboratory measurements are
usually performed on automated clinical
chemistry and immunoassay platforms. They are
available from several providers such as Roche, 
Siemens, Thermo-Fischer, Abbott etc.
In the EUthyroid project, TSH and thyroid 
autoantibody results from various European 
studies are compared after standardisation, 
which is based on reanalysis of a subset of 
samples from each study. The analyses are 
performed at the National Institute for Health 
and Welfare (THL). The ARCHITECT two-step
immunoassays for quantitative determination of 
human serum (or plasma) using
Chemiluminescent Microparticle Immonuassay
(CMIA) technology is used.
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 The most commonly used thyroid-related laboratory measurement
 Used to diagnose thyroid dysfunction and for monitoring of treatment
 Typical additional measurements: free thyroxine (FT4) and thyroid autoantibodies
 Inverse loglinear relationship between TSH and FT4
 TSH measurements are relatively reliable, although results vary by method
3.2  Thyroid stimulating hormone (TSH) 
Spencer 2017. Faix and Miller 2016
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 Thyroid peroxidase autoantibody (TPOAb) and thyroglobulin autoantibody (TgAb)
 Primarily recommended as adjunct to other thyroid measurements
 Measured to diagnose autoimmunity-mediated thyroid dysfunction (mainly TPOAb is used)
 TgAb is primarily used in the clinic as a surrogate tumor marker and adjunct to thyroglobulin (Tg) 
measurement. 
 TgAb is also measured to rule out interference on Tg measurement
 Higher iodine intake increases prevalence of TPOAb, but it is unclear whether occurence of low titers is a 
pathological finding or not.
 Usefulness of antibody measurements is limited by differences in method sensitivity and specificity
 Considerable variability between TPOAb and especially TgAb methods, which hampers comparability of 
numeric results.
3.3  Thyroid autoantibodies
Tozzoli et al. 2016
64
 A standardized fasting time, similar to what is generally recommended for population studies, will yield
more comparable results and allows the use of a single biosample for different analyses. For TSH, non-
fasting samples yield somewhat lower TSH results. In the clinic,  however, fasting is not usually required.
 Circadian rhythm – lower values obtained for TSH if using other than morning samples (up to 30% 
difference)
 Intra-individual variation ~20%. 
 No need for resting prior to blood sampling
 Effect of storage time is small
 Effect of repeated freeze-thaw cycles small
 Use of certain medications may affect TSH measurement and thyroid function (e.g. glucocorticoid
therapy, iodine containing agents) 
 Presence of interferring antibodies may distort laboratory results (rare problem)
 Smoking has adverse effects on thyroid function and impacts on TSH levels
3.4  Effect of preanalytical factors on TSH
Section 2. Thyroid 2003.
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3.5  Preanalytical variables in assessment of thyroid function
Keffer 1996.
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